{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:26:04Z","timestamp":1745468764942,"version":"3.40.4"},"reference-count":15,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Rep Oncol"],"abstract":"<jats:p>Myeloproliferative neoplasms including essential thrombocythemia (ET) is usually caused by somatic mutations in multiple genes, including the JAK2 (most frequently), CALR gene, and MPL. In rare cases, the disease is caused by other mutations such as THPO or TET2 gene; however, around 10\u201315% with ET might have triple-negative mutations. Here we present 2 cases of ET who were asymptomatic on diagnoses, but found to have extremely high platelet counts as never reported earlier. The management and treatment plan can be a challenging step. The objective is to draw attention to the early introduction of thrombocytapheresis in the management of such patients given its notable outcomes. <\/jats:p>","DOI":"10.1159\/000507363","type":"journal-article","created":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T21:01:01Z","timestamp":1591304461000},"page":"606-610","source":"Crossref","is-referenced-by-count":0,"title":["Extreme Levels of Platelet Count in Essential Thrombocythemia: Management and Outcome, Report of Two Cases"],"prefix":"10.1159","volume":"13","author":[{"given":"Mohammad","family":"Abu-Tineh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2020,6,4]]},"reference":[{"key":"ref1","unstructured":"Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, et al. Guidelines on the use of therapeutic apheresis in clinical practice \u2013 evidence-based approach from the writing committee of the American society for apheresis: the eighth special issue. <X00_Journal>J Clin Apher<\/X00_Journal>. 2019 Jun; 34(3):171\u2013354."},{"key":"ref2","unstructured":"Yassin M, Al-Dewik N, ElAyoubi H, Cassinat B. Familial essential thrombocythemia among Qatari tribes. <X00_Journal>Blood, The Journal of the American Society of Hematology<\/X00_Journal>. 2013;122(21):5244."},{"key":"ref3","unstructured":"Yassin M, Al-Dewik N, ElAyoubi H, Cassinat B. Efficacy and safety of pegelated interferon alpha2a once monthly compared to once weekly dose in patients with essential thrombocythemia. <X00_Journal>Blood, The Journal of the American Society of Hematology<\/X00_Journal>. 2013;122(21):4054\u20134054."},{"key":"ref4","unstructured":"Hultcrantz M, Wilkes SR, Kristinsson SY, Andersson TM, Derolf \u00c5R, Eloranta S, et al. Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study. <X00_Journal>J Clin Oncol<\/X00_Journal>. 2015 Jul 10;33(20):2288\u201395."},{"key":"ref5","unstructured":"Srour SA, Devesa SS, Morton LM, Check DP, Curtis RE, Linet MS, et al. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001\u201312. <X00_Journal>Br J Haematol<\/X00_Journal>. 2016 Aug;174(3):382\u201396."},{"key":"ref6","unstructured":"Schafer AI. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. <X00_Journal>Blood<\/X00_Journal>. 2006;107(11):4214, 22."},{"key":"ref7","unstructured":"Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. <X00_Journal>Br J Haematol<\/X00_Journal>. 2005;128(3):275\u201390."},{"key":"ref8","unstructured":"Al-Dewik N, Ben-Omran T, Zayed H, Trujillano D, Kishore S, Rolfs A, et al. Clinical Exome Sequencing unravels new disease-causing mutations in the myeloproliferative neoplasms: a pilot study in patients from the state of Qatar. <X00_Journal>Gene<\/X00_Journal>. 2019 Mar 20;689:34\u20132."},{"key":"ref9","unstructured":"Lancellotti S, Dragani A, Ranalli P, Petrucci G, Basso M, Tartaglione R, et al. Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count. <X00_Journal>J Thromb Haemost<\/X00_Journal>. 2015 Jul;13(7):1226\u201337."},{"key":"ref10","unstructured":"Verger E, Cassinat B, Chauveau A, Dosquet C, Giraudier S, Schlageter MH, et al. Clinical and molecular response to interferon-\u03b1 therapy in essential thrombocythemia patients with CALR mutations. <X00_Journal>Blood<\/X00_Journal>. 2015 Dec 10;126(24):2585\u201391."},{"key":"ref11","unstructured":"Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. <X00_Journal>J Clin Oncol<\/X00_Journal>. 2011 Feb 20;29(6):761\u201370."},{"key":"ref12","unstructured":"Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kr\u00f6ger N, et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <X00_Journal>Ann Oncol<\/X00_Journal>. 2015 Sep 1; 26(Suppl l_5):v85\u201399."},{"key":"ref13","unstructured":"Goldfinger D, Thompson R, Lowe C, Kurz L, Belkin G. Long-term plateletpheresis in the management of primary thrombocytosis. <X00_Journal>Transfusion<\/X00_Journal>. 1979 May 6;19(3):336\u20138."},{"key":"ref14","unstructured":"Patidar GK, Sharma RR, Marwaha N. Frequency of adverse events in plateletpheresis donors in regional transfusion centre in North India. <X00_Journal>Transfus Apher Sci<\/X00_Journal>. 2013 Oct 1;49(2):244\u20138."},{"key":"ref15","unstructured":"Despotis GJ, Goodnough LT, Dynis M, Baorto D, Spitznagel E. Adverse events in platelet apheresis donors: a multivariate analysis in a hospital-based program. <X00_Journal>Vox Sang<\/X00_Journal>. 1999 Aug;77(1):24\u201332."}],"container-title":["Case Reports in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/507363","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/507363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:59:49Z","timestamp":1745423989000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000507363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,4]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,9,22]]}},"URL":"https:\/\/doi.org\/10.1159\/000507363","archive":["Portico"],"relation":{},"ISSN":["1662-6575"],"issn-type":[{"type":"electronic","value":"1662-6575"}],"subject":[],"published":{"date-parts":[[2020,6,4]]}}}